| Date Filed | Type | Description |
| 04/30/2021 |
8-K
| Quarterly results |
| 04/30/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/30/2021 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/30/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/13/2021 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 04/08/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/12/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/01/2021 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 02/17/2021 |
8-K
| Quarterly results |
| 02/12/2021 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 02/11/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2021 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 01/22/2021 |
8-K
| Quarterly results |
| 01/19/2021 |
8-K
| Quarterly results |
| 12/23/2020 |
10-Q
| Quarterly Report for the period ended September 30, 2020 |
| 12/16/2020 |
8-K
| Conference call transcript |
| 12/10/2020 |
8-K
| Appointed a new director|
Docs:
|
"Amended and Restated Articles of Incorporation of Synaptogenix, Inc.",
"Bylaws of Synaptogenix, Inc",
"Separation and Distribution Agreement, by and between Neurotrope, Inc. and Synaptogenix, Inc",
"Tax Matters Agreement, by and between Neurotrope, Inc. and Synaptogenix, Inc",
"SEPARATION AGREEMENT",
"Dr. Alan J. Tuchman",
"SYNAPTOGENIX, INC. 2020 EQUITY INCENTIVE PLAN 1. DEFINITIONS.",
"STOCK OPTION AGREEMENT - INCORPORATED TERMS AND CONDITIONS",
"Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 study and further studies, and continued development of use of Bryostatin-1 for Alzheimer's disease and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual ..." |
|
| 11/20/2020 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 11/12/2020 |
424B1
| Form 424B1 - Prospectus [Rule 424(b)(1)]: |
| 11/10/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/05/2020 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 10/09/2020 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 09/05/2013 |
D
| Form D - Notice of Exempt Offering of Securities |
| 03/13/2013 |
D
| Form D - Notice of Exempt Offering of Securities |